Stoke Therapeutics (STOK)

Executive Summary

Stoke Therapeutics is a clinical-stage RNA medicine company pioneering a novel approach to treat severe genetic disorders by restoring protein expression from healthy genes. Its proprietary TANGO platform uses antisense oligonucleotides to upregulate functional protein production, addressing the root cause of haploinsufficiency diseases. The company's lead program, zorevunersen (STK-001), is in Phase 3 development for Dravet syndrome, a devastating childhood epilepsy with high unmet medical need. Stoke has completed Phase 1/2 studies demonstrating promising seizure reduction and favorable safety, and a pivotal Phase 3 trial (NCT06872125) is actively recruiting. With a strong intellectual property position and a validated platform, Stoke is well-positioned to become a leader in RNA-targeted therapies. The company's near-term value hinges on successful execution of the Phase 3 trial and potential regulatory milestones, including possible breakthrough therapy designation. Financial strength from public markets and a focused pipeline support its path to commercialization.

Upcoming Catalysts (preview)

• Q2 2027Phase 3 interim efficacy analysis for zorevunersen in Dravet syndrome75% success
• Q4 2026FDA breakthrough therapy designation for STK-00165% success
• Q3 2026Initiation of Phase 2/3 trial for next TANGO program (e.g., STK-002 in autosomal dominant optic atrophy)80% success